Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.

ABSTRACT: Successful therapeutic options remain elusive for pancreatic cancer. The exquisite sensitivity and specificity of humoral and cellular immunity may provide therapeutic approaches if antigens specific for pancreatic cancer cells can be identified. Here we characterize SAS1B (ovastacin, ASTL, astacin-like), a cancer-oocyte antigen, as an attractive immunotoxin target expressed at the surface of human pancreatic cancer cells, with limited expression among normal tissues. Immunohistochemistry shows that most pancreatic cancers are SAS1B^pos (68%), while normal pancreatic ductal epithelium is SAS1B^neg. Pancreatic cancer cell lines developed from patient-derived xenograft models display SAS1B cell surface localization, in addition to cytoplasmic expression, suggesting

SUBMITTER: Knapp KA 

PROVIDER: S-EPMC5823626 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature